A PHASE I SAFETY AND PHARMACOKINETIC STUDY OF EVEROLIMUS, AN ORAL MTOR INHIBITOR, IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION ArticlePeveling-Oberhag J., Zeuzem S., Yong W.P., Kunz T., Paquet T., Bouillaud E., Urva S., Anak O., Sellami D., Kobalava Z.EUROPEAN JOURNAL OF CANCER. Том 47. 2011.
INFLAMMATION RESEARCH Conference proceedings40th Annual Meeting of the European-Histamine-Research-Society. SPRINGER BASEL AG.